
Soliton, Inc. Net Income 2011-2026 | SOLY
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Soliton, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -14.5 M | -13.8 M | -9.31 M | -7.48 M | -7.3 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.3 M | -14.5 M | -10.5 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
421 M | $ 176.83 | 5.97 % | $ 13.2 B | ||
|
Alphatec Holdings
ATEC
|
-143 M | $ 11.66 | 5.71 % | $ 1.75 B | ||
|
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-81.7 M | - | -26.83 % | $ 2.62 M | ||
|
AxoGen
AXGN
|
-15.7 M | $ 34.0 | 9.71 % | $ 1.57 B | ||
|
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 12.18 | 2.01 % | $ 1.65 B | ||
|
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | ||
|
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | ||
|
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
-716 M | $ 281.15 | 1.13 % | $ 7.93 B | ||
|
Second Sight Medical Products
EYES
|
-26.6 M | - | -0.97 % | $ 54.4 M | ||
|
Bruker Corporation
BRKR
|
113 M | $ 38.25 | 4.31 % | $ 5.7 K | ||
|
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | ||
|
Boston Scientific Corporation
BSX
|
2.89 B | $ 62.56 | 1.15 % | $ 92.6 B | ||
|
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | ||
|
Electromed
ELMD
|
7.54 M | $ 24.4 | 2.61 % | $ 206 M | ||
|
ClearPoint Neuro
CLPT
|
-25.5 M | $ 9.17 | 1.1 % | $ 260 M | ||
|
Globus Medical
GMED
|
538 M | $ 91.96 | 2.13 % | $ 12.4 B | ||
|
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | ||
|
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | ||
|
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
-72.5 M | $ 4.14 | 2.22 % | $ 876 M | ||
|
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | ||
|
Nevro Corp.
NVRO
|
-113 M | - | - | $ 217 M | ||
|
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.62 | 1.67 % | $ 38.6 M | ||
|
EDAP TMS S.A.
EDAP
|
-21.2 M | $ 3.37 | -0.88 % | $ 126 M | ||
|
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
2.7 M | $ 9.85 | 1.86 % | $ 353 M | ||
|
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | ||
|
CONMED Corporation
CNMD
|
47.1 M | $ 36.59 | 5.94 % | $ 1.14 B | ||
|
FONAR Corporation
FONR
|
12.4 M | $ 18.62 | 0.22 % | $ 122 M | ||
|
Edwards Lifesciences Corporation
EW
|
1.07 B | $ 81.71 | 1.08 % | $ 47.8 B | ||
|
Inspire Medical Systems
INSP
|
145 M | $ 53.38 | -1.89 % | $ 1.57 B | ||
|
Varex Imaging Corporation
VREX
|
-70.3 M | $ 11.04 | 4.25 % | $ 457 M | ||
|
Helius Medical Technologies
HSDT
|
-8.85 M | $ 1.88 | 2.73 % | $ 1.14 M | ||
|
Inogen
INGN
|
-22.7 M | $ 6.67 | -1.91 % | $ 177 M | ||
|
IRIDEX Corporation
IRIX
|
-4.44 M | $ 1.03 | - | $ 17.4 M | ||
|
Integer Holdings Corporation
ITGR
|
103 M | $ 87.48 | 2.78 % | $ 3.04 B | ||
|
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 16.01 | 1.59 % | $ 376 M |